By:DengYue International Business Division

As global demand for GLP-1 therapies continues to surge, the pharmaceutical industry is entering a new phase of competition.

In the past, industry attention focused primarily on drug development, clinical data, and weight-loss efficacy. Today, however, more pharmaceutical companies are beginning to realize that the key factor determining market scale and long-term supply capability is becoming: who can provide sufficient large-scale peptide manufacturing capacity.

As a participant continuously following the development of global peptide APIs and innovative pharmaceutical supply chains, HongKong DengYueMed has been closely monitoring changes throughout the GLP-1 industry chain. Especially with the rapid development of semaglutide, tirzepatide, and next-generation triple agonists such as retatrutide, the global peptide manufacturing industry is entering an unprecedented expansion cycle.

From Chinese CDMOs to multinational pharmaceutical companies in Europe and the United States, more and more companies are accelerating the construction of GLP-1 peptide production facilities, expanding SPPS manufacturing lines, increasing purification systems, and strengthening lyophilization capabilities to meet continuously growing global market demand.

Why Has GLP-1 Manufacturing Capacity Become a Global Bottleneck?

Unlike traditional small-molecule drugs, GLP-1 therapies belong to the category of complex peptide drugs and require significantly more sophisticated manufacturing systems.

Large-scale GLP-1 production typically involves:

● Solid-phase peptide synthesis (SPPS)

● Long-chain peptide assembly

● High-purity purification systems

● Strict impurity control

● Lyophilization processes

● Cold-chain logistics systems

As the GLP-1 market expands from diabetes treatment into the global obesity market, demand has already surpassed the scale of the traditional peptide drug era.

What has become truly scarce is no longer simply the GLP-1 molecule itself, but rather the industrial-scale manufacturing capability required to achieve stable, continuous, and large-scale commercial production.

Against this backdrop, the global peptide CDMO and API manufacturing industry has entered a new round of capacity expansion.

WuXi AppTec Continues Expanding Peptide Manufacturing Capacity

Among China’s peptide expansion wave, WuXi AppTec has become one of the industry’s most closely watched companies.

In recent years, the company has continuously expanded peptide manufacturing facilities in Changzhou and Taixing, including the addition of large-scale peptide production workshops, increased reactor volume, and strengthened commercial manufacturing capabilities.

One major focus of industry attention is WuXi AppTec’s increasingly integrated CDMO platform covering:

● Peptide synthesis

● Purification

● Analytical testing

● Process development

● Commercial manufacturing

As GLP-1 demand continues to rise, more pharmaceutical companies are no longer simply seeking outsourcing manufacturers, but instead strategic supply partners capable of providing long-term supply security and globally compliant quality systems.

This is one of the key reasons why large-scale peptide CDMOs are becoming increasingly valuable.

Aurisco Pharmaceutical Accelerates GLP-1 Capacity Expansion

Aurisco Pharmaceutical is also accelerating its GLP-1 peptide manufacturing expansion.

In recent years, the company has continued investing in new cGMP peptide manufacturing workshops while strengthening large-scale GLP-1 API production capabilities.

This reflects a major industry trend:

An increasing number of Chinese manufacturers are no longer limiting themselves to small-scale clinical-stage production, but are instead preparing for:

● Commercial-scale supply

● Multi-ton manufacturing capacity

● Long-term API contracts

● International regulatory compliance systems

The peptide industry is gradually transitioning from a niche high-value-added segment into a truly industrial-scale manufacturing industry.

Hybio Pharmaceutical and China’s Industrial Cluster Advantages

Hybio Pharmaceutical is another important participant in China’s peptide expansion landscape.

Over the past several years, China’s peptide supply chain ecosystem has rapidly matured, gradually forming a comprehensive industrial system covering:

● Amino acid raw materials

● Coupling reagents

● SPPS engineering systems

● Purification equipment

● Analytical testing

● GMP manufacturing

The value of this industrial ecosystem goes far beyond cost advantages alone.

More importantly, it significantly improves the industry’s:

● Responsiveness

● Process replication capability

● Expansion efficiency

● Supply-chain stability

The Yangtze River Delta region, in particular, has gradually become one of the world’s most concentrated peptide manufacturing clusters.

In many cases, the competitiveness of China’s peptide industry comes not only from individual companies, but from the coordinated capabilities of the entire industrial ecosystem.

Novo Nordisk and Eli Lilly Are Also Strengthening Global Supply Networks

GLP-1 expansion is not occurring only within the CDMO sector.

Major multinational pharmaceutical companies including Novo Nordisk and Eli Lilly and Company are also continuously strengthening their global manufacturing networks.

Over the past several years, due to persistent GLP-1 shortages and supply constraints, both companies have accelerated efforts involving:

● Facility expansion

● External CDMO partnerships

● Contract manufacturing systems

● Multi-source supply strategies

The industry is increasingly recognizing that relying on a single manufacturing source creates substantial risks under rapidly growing GLP-1 demand conditions.

As a result, dual-sourcing systems and diversified API procurement strategies are becoming increasingly common among pharmaceutical companies.

Why Is Expansion Speed Becoming Increasingly Important?

One of the defining characteristics of the GLP-1 market is the extraordinary speed of demand growth.

Meanwhile, traditional pharmaceutical manufacturing expansion cycles are often lengthy, involving:

● Facility construction

● GMP validation

● Equipment commissioning

● Process scale-up

which can require several years to complete.

However, the growth rate of the GLP-1 market has already exceeded many companies’ original expectations.

This gives clear advantages to manufacturers capable of rapidly achieving:

● Production-line deployment

● Multi-project switching

● Parallel development

● Process optimization

At this stage, manufacturing execution efficiency is becoming nearly as important as drug innovation itself.

GLP-1 Competition Is Shifting from “Drug Competition” to “Manufacturing Competition”

The deeper significance of the GLP-1 boom is that it is reshaping how the global pharmaceutical industry views manufacturing capability.

In the past, peptide manufacturing was considered a specialized niche within the broader API sector.

Today, however, it is gradually becoming a strategic industrial capability within the global pharmaceutical industry.

Over the next several years, competition within the GLP-1 industry may no longer focus solely on “who has the better molecule,” but increasingly on:

who can truly establish stable, scalable, and sustainable global supply systems.

This is also why global capital markets and multinational pharmaceutical companies are paying unprecedented attention to peptide CDMOs and API manufacturing capabilities.

Conclusion

The GLP-1 industry is currently driving one of the largest peptide manufacturing expansion cycles the global pharmaceutical industry has seen in recent years.

From Chinese peptide CDMOs to multinational pharmaceutical companies in Europe and the United States, the entire industry is entering a new round of competition centered around manufacturing capacity.

Companies such as WuXi AppTec, Aurisco Pharmaceutical, Hybio Pharmaceutical, Novo Nordisk, and Eli Lilly are all continuing to expand GLP-1-related manufacturing infrastructure in order to meet rapidly growing global demand.

For the global pharmaceutical supply chain, the significance of GLP-1 extends far beyond a single drug cycle. It is driving the entire peptide manufacturing industry toward larger-scale, higher-efficiency, and more supply-resilient systems.

As a participant continuously focused on China’s peptide API industry and the global innovative pharmaceutical supply chain, DengYueMed will continue monitoring the development trends of GLP-1 and next-generation peptide therapeutics, connecting high-quality Chinese peptide API resources with international market demand while providing partners with more stable, high-quality, and scalable supply-chain support.